The continued osimertinib plus chemotherapy overcoming resistance after histologic transformation in EGFR-mutant lung adenocarcinoma treated with osimertinib.

被引：0
|
作者：
Kang, Jin
Li, Xiang-Meng
Cheng, Jia-Tao
Chen, Huajun
Zhang, Xuchao
Tu, Hai-Yan
Zhou, Qing
Wu, Yi-Long
Yang, Jin-Ji
机构：
[1] Guangdong Prov Peoples Hosp, Guangdong Lung Canc Inst, Guangzhou, Guangdong, Peoples R China
[2] Guangdong Acad Med Sci, Guangzhou, Guangdong, Peoples R China
[3] Guangdong Prov Peoples Hosp, Guangdong Lung Canc Inst, Guangdong Prov Key Lab Translat Med Lung Canc, Guangzhou, Guangdong, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
10.1200/JCO.2019.37.15_suppl.e20615
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e20615
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Overcoming acquired resistance following osimertinib administration in EGFR-mutant lung adenocarcinoma
    Kaira, Kyoichi
    Imai, Hisao
    Kagamu, Hiroshi
    [J]. TRANSLATIONAL LUNG CANCER RESEARCH, 2024, 13 (05) : 1177 - 1182
  • [2] Rhabdomyosarcomatous Transformation as a Mechanism of Resistance to Osimertinib and Savolitinib in EGFR-Mutant Lung Adenocarcinoma With METamp After Osimertinib First-Line Treatment
    Corassa, Marcelo
    Abreu, Rodrigo Fonseca
    Cordeiro de Lima, Vladmir Claudio
    Torrezan, Giovana Tardim
    Cavalher, Felicia Peterson
    Silva, Tullio Novaes
    de Oliveira, Thiago Bueno
    Freitas, Helano Carioca
    Carraro, Dirce Maria
    Costa, Felipe D'Almeida
    [J]. JCO PRECISION ONCOLOGY, 2022, 6
  • [3] Safety of osimertinib plus chemotherapy in EGFR-mutant NSCLC
    Piotrowska, Zofia
    Liu, Stephen V.
    Muzikansky, Alona
    Marcoux, Nicolas
    Banwait, Mandeep
    Stevens, Sara
    Goodwin, Kelly
    Lafferty, Tracey E.
    Ackil, Jennifer
    Krueger, Elizabeth A.
    Heist, Rebecca Suk
    Lin, Jessica Jiyeong
    Gainor, Justin F.
    Hata, Aaron N.
    Shaw, Alice Tsang
    Sequist, Lecia V.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [4] EGFR-mutant lung adenocarcinoma associated with antisynthetase syndrome successfully treated with osimertinib
    Hara, Reina
    Kanazu, Masaki
    Iwai, Ami
    Kuge, Tomoki
    Ishijima, Mikako
    Uenami, Takeshi
    Akazawa, Yuki
    Yano, Yukihiro
    Yamaguchi, Toshihiko
    Mori, Masahide
    [J]. THORACIC CANCER, 2021, 12 (09) : 1441 - 1444
  • [5] Osimertinib Rechallenge With Bevacizumab vs. Chemotherapy Plus Bevacizumab in EGFR-Mutant NSCLC Patients With Osimertinib Resistance
    Cui, Qingli
    Hu, Yanhui
    Cui, Qingan
    Wu, Daoyuan
    Mao, Yuefeng
    Ma, Dongyang
    Liu, Huaimin
    [J]. FRONTIERS IN PHARMACOLOGY, 2022, 12
  • [6] Capmatinib and Osimertinib Combination Therapy for EGFR-Mutant Lung Adenocarcinoma
    Gautschi, Oliver
    Menon, Roopika
    Bertrand, Miriam
    Murer, Christian
    Diebold, Joachim
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2020, 15 (01) : E13 - E15
  • [7] Combatting acquired resistance to osimertinib in EGFR-mutant lung cancer
    Lee, Jiyun
    Piotrowska, Zofia
    Soo, Ross
    Cho, Byoung Chul
    Lim, Sun Min
    [J]. THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2022, 14
  • [8] Successful Treatment of EGFR-Mutant Synchronous SCLC and Lung Adenocarcinoma With Osimertinib
    Batra, Ullas
    Nathany, Shrinidhi
    Sharma, Mansi
    Mehta, Anurag
    Jain, Parveen
    Bansal, Abhishek
    [J]. JTO CLINICAL AND RESEARCH REPORTS, 2021, 2 (01):
  • [9] Early Detection of Multiple Resistance Mechanisms by ctDNA Profiling in a Patient With EGFR-mutant Lung Adenocarcinoma Treated With Osimertinib
    Schmid, Sabine
    Stewart, Erin L.
    Martins-Filho, Sebastiao N.
    Cabanero, Michael
    Wang, Ao
    Bao, Hua
    Wu, Xue
    Patel, Deval
    Chen, Zhuo
    Law, Jennifer H.
    Bradbury, Penelope A.
    Shepherd, Frances A.
    Leighl, Natasha
    Tsao, Ming-Sound
    Pugh, Trevor
    Bratman, Scott, V
    Sacher, Adrian
    Liu, Geoffrey
    [J]. CLINICAL LUNG CANCER, 2020, 21 (05) : E488 - E492
  • [10] Impact of next-generation sequencing on clinical outcomes in advanced EGFR-mutant lung cancer patients after resistance to osimertinib.
    Cheng, Jia-Tao
    Yang, Jin-Ji
    Wu, Yi-Long
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345